Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

TNBC response to paclitaxel phenocopies interferon response which reveals cell cycle-associated resistance mechanisms

Scientific Reports(2025)10.1038/s41598-024-82218-9Source: DataRank Database

TNBC response to paclitaxel phenocopies interferon response which reveals cell cycle-associated resistance mechanisms is a research paper published in Scientific Reports (2025). On theSindex it has a DataRank of 0.379. It has been cited 7 times, with 7 citing works in its 1-hop citation network.

N/A

0.379DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access7 citations · 7 citing works in its network

Download PDF

Cite:

Data availability

Repositories this paper deposited data in (declared in PubMed).

GEOGSE266934

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 2.68)OA: goldTopics (53)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 82%Citation Network 18%

Base Score Contribution

0.312

From this paper's citation signal

Citation Network Contribution

0.0668

From 2 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 7 citers.

Therapeutic resistance and combination therapy for cancer: recent developments and future directions
Scientific Reports202512 citations37 referencesContributes 0.069
The role of long non-coding RNAs in developing paclitaxel-resistant triple negative breast cancer: a systematic review
Cancer Treatment and Research Communications20251 citations75 referencesContributes 0.009
Interferons as therapeutic orchestrators of cancer stem cell plasticity and therapy response
Cytokine & Growth Factor Reviews20250 citations103 referencesContributes 0.000
Synergistic anti-tumor effects of novel two-domain soluble Fms-like tyrosine kinase-1 and paclitaxel on three-dimensional breast cancer models: implications for targeted therapy
Journal of Translational Medicine20250 citations43 referencesContributes 0.000
Ex vivo organotypic culture of liposarcoma effectively models in vivo supratherapeutic paclitaxel localized drug delivery
Translational Oncology20260 citations42 referencesContributes 0.000

Authors (7)

Tiera Liby ORCID,Zhi Hu ORCID,Hongmei Zhang ORCID,Mark Dane ORCID,Sean M. Gross ORCID

Live enrichment

PubMed:39905117 PMC:PMC11794704 OpenAlex:https://openalex.org/W4407125261

U.S. Department of Health & Human Services | NIH | National Cancer Institute

Grant: U54-CA209988

U.S. Department of Health & Human Services | NIH | National Cancer Institute

Grant: P30CA069533

U.S. Department of Health & Human Services | NIH | National Cancer Institute

Grant: T32CA254888

NCI NIH HHS

Grant: U54 CA209988

FWCI

2.68

Citation Percentile

0.9%

Citation Trend

2025

2026

goldLicense: cc-by

journalhttps://doi.org/10.1038/s41598-024-82218-9

publisherhttps://doi.org/10.1038/s41598-024-82218-9

publisherhttps://www.nature.com/articles/s41598-024-82218-9.pdf

publisherhttps://www.nature.com/articles/s41598-024-82218-9

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39905117

Fields of Study

Single-cell and spatial transcriptomicsImmune cells in cancerinterferon and immune responsesPaclitaxelHumansTriple Negative Breast NeoplasmsCell Line, TumorFemaleDrug Resistance, NeoplasmCell CycleGene Expression Regulation, NeoplasticApoptosisCell ProliferationAntineoplastic Agents, PhytogenicInterferonsTranscription FactorsTumor Microenvironment

MeSH Terms

Antineoplastic Agents, PhytogenicCell CycleDNA DamageFemaleHumansInterferonsTranscription FactorsGene Expression Regulation, NeoplasticApoptosisPaclitaxelDrug Resistance, NeoplasmCell Line, TumorCell ProliferationTumor MicroenvironmentTriple Negative Breast Neoplasms

Keywords

PaclitaxelCell cycleDownregulation and upregulationCancer researchGene knockdownCell cycle checkpointCellTriple-negative breast cancerTranscription factorBiologyCell growthBreast cancerMedicineCancerApoptosisInternal medicineGeneLive-cell ImagingInterferon ResponseTriple Negative Breast Cancer (Tnbc)Single-cell Rna Sequencing (Scrna-seq)

Sustainable Development Goals

SDG 0: Good health and well-being